Although NS and LS share common clinical features, SHP2 mutations are activating in NS due to increased phosphatase activity and inactivating in LS because of an inhibition of the catalytic activity of the phosphatase [72, 73]. This evidence concerns the gene PTPN11 and Leigh syndrome.